局晚期不可切除非小细胞肺癌放免联合治疗的研究进展

Radiotherapy is an important local treatment for locally advanced unresectable non-small cell lung cancer (NSCLC). The advent of the immune era has brought a new breakthrough for systemic therapy, and immunoconsolidation therapy after concurrent chemoradiotherapy can significantly improve the overall survival of patients with unresectable stage Ⅲ NSCLC. However, in the treatment of locally advanced unresectable NSCLC, the phase Ⅲ clinical trials of immunotherapy combined with radiotherapy, such as concurrent, induction, and chemotherapy free mode, are still limited, and some of the clinical trial results are negative, suggesting that the efficacy of different combined treatment strategies still needs to be further verified. In this paper, the mechanism research and clinical progress of radiotherapy combined with immunotherapy in locally advanced unresectable NSCLC in recent years are reviewed, and it is proposed that different combined treatment modes should be provided to guide individualized precision treatment according to patients in the future.